Related Experiment Video
Updated: Dec 18, 2025
13:01
Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
136.8K
Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets
Michael Mahler1, Marie Hudson2, Chelsea Bentow1
1Inova Diagnostics, Inc., San Diego, CA, USA.
Autoimmunity Reviews
|June 20, 2020
Summary
Systemic sclerosis (SSc) is a rare autoimmune disease affecting multiple organs. This review explores autoantibodies and new strategies to classify SSc into actionable patient subsets for better treatment.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Systemic sclerosis (SSc) is a rare, chronic autoimmune disease of unknown cause.
- Characterized by vascular damage and fibrosis affecting skin and internal organs (gastrointestinal, lung, heart, kidneys).
- Current treatments are limited, impacting quality of life and survival.
Purpose of the Study:
- To review the role of autoantibodies in SSc.
- To present novel approaches for stratifying SSc into clinically actionable subsets.
Main Methods:
- Literature review of autoantibodies in SSc.
- Analysis of recent stratification strategies based on organ involvement.
Main Results:
- Autoantibodies are key biomarkers in SSc.
- Stratification by internal organ involvement offers a more clinically relevant approach than skin extent alone.
- Emerging classification methods aim for personalized treatment strategies.
Conclusions:
- Understanding autoantibody profiles is crucial for SSc management.
- Novel stratification approaches promise more targeted therapies and improved patient outcomes.
- Further research into SSc subsets can lead to disease-modifying treatments.
